Joshi, Poorvashree’s team published research in Pharmacological Reports in 71 | CAS: 1219707-39-7

Pharmacological Reports published new progress about 1219707-39-7. 1219707-39-7 belongs to oxazolidine, auxiliary class Other Aliphatic Heterocyclic,Oxazolidine,Chiral,Fluoride,Benzene,Amide,Alcohol,Anti-infection, name is (R)-3-(3-Fluoro-4-(1-methyl-5,6-dihydro-1,2,4-triazin-4(1H)-yl)phenyl)-5-(hydroxymethyl)oxazolidin-2-one, and the molecular formula is C14H17FN4O3, COA of Formula: C14H17FN4O3.

Joshi, Poorvashree published the artcileUnlocking the concealed targets using system biology mapping for Alzheimer′s disease, COA of Formula: C14H17FN4O3, the publication is Pharmacological Reports (2019), 71(6), 1104-1107, database is CAplus and MEDLINE.

Alzheimer′s disease (AD) constitutes a neural loss in histol. of brain with involvement of complex genomic and environmental factors. Accumulation of amyloid beta (Aβ) peptide and phosphorylated tau are indicative of progression and cognitive decline. Hence an understanding of the underlying biol. pathways and targets along with associated mechanisms would be useful for the development of improved therapeutics for treating AD. In the present work, we aim to identify concealed targets for developing first line therapeutics and repositioning of validated targets as well as FDA- approved drugs using a system biol. approach. We have collated information pertaining to the biol. targets as well as the approved drugs, from scientific literature and patents. In all, the imbalance in the functioning of around 79 proteins and genes were identified to be involved in Alzheimer′s cascade. Amongst them, around 21 targets were found to be under therapeutic consideration for AD. Of the remaining, around 17 targets were reported as potential targets for AD, although they are under researcher′s attention for other physio-pathol. conditions. The anal. further revealed that âˆ?1 therapeutic targets are pharmacol. concealed but structurally validated targets and may constitute as potential therapeutic candidate for future drug discovery for AD.The biol. pathway vs. drug mapping provides a complete overview about underlying biol. pathways, therapeutic targets (explored and concealed), associated mechanisms, existing therapeutics and the information pertaining to mols. currently under active drug development for further drug discovery and drug re-positioning/repurposing approaches for AD management.

Pharmacological Reports published new progress about 1219707-39-7. 1219707-39-7 belongs to oxazolidine, auxiliary class Other Aliphatic Heterocyclic,Oxazolidine,Chiral,Fluoride,Benzene,Amide,Alcohol,Anti-infection, name is (R)-3-(3-Fluoro-4-(1-methyl-5,6-dihydro-1,2,4-triazin-4(1H)-yl)phenyl)-5-(hydroxymethyl)oxazolidin-2-one, and the molecular formula is C14H17FN4O3, COA of Formula: C14H17FN4O3.

Referemce:
https://en.wikipedia.org/wiki/Oxazolidine,
Oxazolidine | C3H7NO – PubChem